Peptides for Cognition
Research overview of peptides studied for cognitive function, memory, and neuroprotection. Semax, selank, dihexa, and nootropic peptide evidence.
Research Overview
Cognitive peptide research includes nootropics (cognition enhancers), neuroprotective compounds, and peptides studied for neurodegenerative conditions. The field spans approved medications in some countries (semax, selank in Russia) to highly experimental compounds (dihexa, cerebrolysin).
Semax and selank are among the most studied cognitive peptides, with documented anxiolytic and potential nootropic effects. Both are approved in Russia but not in Western markets. Cerebrolysin, a porcine brain-derived peptide mixture, has extensive research primarily in post-stroke recovery and neurodegenerative conditions.
Dihexa and similar experimental peptides have shown remarkable effects in preclinical models but lack human safety and efficacy data. Researchers should carefully distinguish between peptides with human clinical evidence and those with only animal data.
Key Cognitive Peptides
Semax
Status: Approved in Russia
| Aspect | Details |
|---|---|
| Mechanism | ACTH analog, BDNF modulation |
| Indications (RU) | Cognitive disorders, stroke |
| Evidence | Moderate (Russian literature) |
| Western trials | Limited |
Selank
Status: Approved in Russia
| Aspect | Details |
|---|---|
| Mechanism | Tuftsin analog, anxiolytic |
| Indications (RU) | Anxiety, cognitive support |
| Evidence | Low-Moderate |
| Anxiolytic effects | Better documented |
Cerebrolysin
Status: Approved in many countries (not US)
| Research Area | Evidence Level |
|---|---|
| Stroke recovery | Moderate |
| Dementia/AD | Low-Moderate |
| Cognitive function | Low-Moderate |
Porcine brain-derived peptide mixture with extensive research, though quality varies.
Dihexa
Status: Experimental only
| Aspect | Details |
|---|---|
| Mechanism | HGF/c-Met pathway |
| Animal data | Potent in models |
| Human data | None |
| Safety | Unknown |
Preclinical data intriguing but no human safety or efficacy data.
Evidence Hierarchy
- Most evidence: Cerebrolysin (for specific indications)
- Moderate evidence: Semax, Selank (Russian approval)
- Limited evidence: NA-Semax, NA-Selank variants
- Preclinical only: Dihexa, P21, experimental nootropics
Research Limitations
- Russian literature requires careful evaluation
- Western clinical trials limited for approved compounds
- Experimental peptides lack safety data
- Cognitive outcomes difficult to measure objectively
Peptides Studied for Cognition
No peptides currently documented for this condition. Check back for updates.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. The peptides listed may or may not have regulatory approval. Always consult a qualified healthcare provider before making any health decisions.